Results: ReposiTrak, Inc. Beat Earnings Expectations And Analysts Now Have New Forecasts
As you might know, ReposiTrak, Inc. (NYSE:TRAK) recently reported its full-year numbers. ReposiTrak reported US$23m in revenue, roughly in line with analyst forecasts, although statutory earnings per share (EPS) of US$0.39 beat expectations, being 5.4% higher than what the analyst expected. Following the result, the analyst has updated their earnings model, and it would be good to know whether they think there's been a strong change in the company's prospects, or if it's business as usual. So we gathered the latest post-earnings forecasts to see what estimate suggests is in store for next year.
After the latest results, the solitary analyst covering ReposiTrak are now predicting revenues of US$25.5m in 2027. If met, this would reflect a solid 9.5% improvement in revenue compared to the last 12 months. Per-share earnings are expected to accumulate 5.7% to US$0.43. Yet prior to the latest earnings, the analyst had been anticipated revenues of US$26.0m and earnings per share (EPS) of US$0.42 in 2027. The analyst seem to have become more bullish on the business, judging by their new earnings per share estimates.
Check out our latest analysis for ReposiTrak
The average the analyst price target fell 45% to US$16.00, suggesting thatthe analyst has other concerns, and the improved earnings per share outlook was not enough to allay them.
Another way we can view these estimates is in the context of the bigger picture, such as how the forecasts stack up against past performance, and whether forecasts are more or less bullish relative to other companies in the industry. It's clear from the latest estimates that ReposiTrak's rate of growth is expected to accelerate meaningfully, with the forecast 9.5% annualised revenue growth to the end of 2027 noticeably faster than its historical growth of 4.7% p.a. over the past five years. Compare this with other companies in the same industry, which are forecast to see revenue growth of 17% annually. So it's clear that despite the acceleration in growth, ReposiTrak is expected to grow meaningfully slower than the industry average.
The Bottom Line
The biggest takeaway for us is the consensus earnings per share upgrade, which suggests a clear improvement in sentiment around ReposiTrak's earnings potential next year. On the plus side, there were no major changes to revenue estimates; although forecasts imply they will perform worse than the wider industry. The consensus price target fell measurably, with the analyst seemingly not reassured by the latest results, leading to a lower estimate of ReposiTrak's future valuation.
With that in mind, we wouldn't be too quick to come to a conclusion on ReposiTrak. Long-term earnings power is much more important than next year's profits. At least one analyst has provided forecasts out to 2028, which can be seen for free on our platform here.
Another thing to consider is whether management and directors have been buying or selling stock recently. We provide an overview of all open market stock trades for the last twelve months on our platform, here.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.